338453-16-0 Usage
Description
Cyclobutanesulfonyl chloride is an organic compound with the chemical formula C4H7ClO2S. It is a colorless to pale yellow liquid that is soluble in water and various organic solvents. Cyclobutanesulfonyl chloride is a valuable reagent in organic synthesis, particularly in the formation of sulfonamide derivatives and as a protecting group for amines.
Uses
Used in Chemical Synthesis:
Cyclobutanesulfonyl chloride is used as a reagent for the synthesis of sulfonamides, which are important compounds in the pharmaceutical industry. It reacts with amines to form N-acylsulfonamides, which can be further transformed into various biologically active molecules.
Used in Biochemistry and Molecular Biology:
Cyclobutanesulfonyl chloride is used as a chemical tool for studying the paralog-specific function of IRE1 (Inositol-requiring enzyme 1). IRE1 is a type I transmembrane protein kinase and endoribonuclease that plays a crucial role in the unfolded protein response (UPR) in cells. By using cyclobutanesulfonyl chloride, researchers can selectively modify and study the function of different IRE1 paralogs, which can help in understanding their roles in cellular processes and potential therapeutic applications.
Used in Drug Development:
Cyclobutanesulfonyl chloride can be employed in the development of novel drugs targeting IRE1 and other related proteins. By creating specific inhibitors or activators of these proteins, researchers can potentially develop new therapeutic strategies for treating various diseases, including neurodegenerative disorders and cancer.
Check Digit Verification of cas no
The CAS Registry Mumber 338453-16-0 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 3,3,8,4,5 and 3 respectively; the second part has 2 digits, 1 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 338453-16:
(8*3)+(7*3)+(6*8)+(5*4)+(4*5)+(3*3)+(2*1)+(1*6)=150
150 % 10 = 0
So 338453-16-0 is a valid CAS Registry Number.
338453-16-0Relevant articles and documents
REV-ERB AGONISTS FOR THE TREATMENT OF TH17-MEDIATED INFLAMMATORY DISORDERS
-
Paragraph 001927-001929, (2022/01/05)
The present disclosure provides compounds of Formula IA and Formula IB and their pharmaceutical compositions as selective agonists of REV-ERB-α: where R1, R2, R3, R4, R5, RX1, RX2, nA, nB, X, Y, and Z are described herein. The compounds are useful in various methods and uses, such as in the treatment of diseases including hyperglycemia, dyslipidemia, atherosclerosis, and autoimmune and inflammatory disorders or diseases, and as cancer therapeutics, such as for the treatment of glioblastoma, hepatocellular carcinoma, and colorectal cancer, and for immune-oncology purposes.
INDAZOLE ANALOGUE
-
Page/Page column 78, (2012/08/14)
[Objective] To provide a drug that selectively stimulates the β3-adrenergic receptors, particularly a drug capable of preferentially stimulating the β3-adrenergic receptors over the α1-adrenergic receptors. This drug can be used in the treatment and prevention of diabetes, obesity, hyperlipidemia, depression, cholelithiasis, diseases caused by biliary hyperkinesia, diseases caused by hyperfunction of the gastrointestinal tract, interstitial cystitis, overactive bladder or urinary incontinence, diseases associated with decreased lacrimation, and the like. [Solution] Indazole analogs represented by the general formula (I) or a salt thereof. Drugs that contains these indazole analogs or a salt thereof as the active ingredient.
CYCLOPROPYL FUSED INDOLOBENZAZEPINE HCV NS5B INHIBITORS
-
Page/Page column 109-110, (2009/06/27)
The invention encompasses compounds of formula (I) as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV